On December 3, 2023 Ideaya Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported agenda topics for its Investor R&D Day (Press release, Ideaya Biosciences, DEC 3, 2023, View Source [SID1234638107]). The webcast event will be hosted by IDEAYA on Monday, December 4, 2023 at 8:00 am to 9:30 am ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations by IDEAYA management and key opinion leaders will showcase scientific insights and clinical development opportunities across IDEAYA’s synthetic lethality pipeline, including IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, GSK101/IDE705 (Pol Theta Helicase) in Phase 1, and the Werner Helicase program for which an IND submission is planned for 2024. In addition, IDEAYA will highlight its next generation initiatives for MTAP-deletion, that include a wholly-owned program where a development candidate nomination is targeted in 2024 and multiple first-in-class clinical combination opportunities. The IDEAYA Investor R&D Day Webcast agenda will be the following:
Agenda Topics
The Synthetic Lethality Paradigm
IDEAYA Vision, Strategy and Pipeline (Yujiro S. Hata, CEO)
Computational Drug Discovery
Overview of Current Approaches at IDEAYA (Mike White, CSO)
IDE161 Clinical Data and Program Updates (Timothy Yap, MD Anderson)
Emerging Therapeutic Opportunities for MTAP-deletion
IDEAYA’s Multiple-Pronged Strategy (Mike White, CSO; Darrin Beaupre, CMO)
IDEAYA and GSK Partnership
Pol Theta Helicase and Werner Helicase Programs (Ramon Kemp, GSK)
Key Opinion Leader Presenters
Timothy Yap, M.D., Associate Professor, Department for Investigational Cancer Therapeutics and Department of Thoracic/Head and Neck Medical Oncology, Medical Director, Institute for Applied Cancer Science, Associate Director of Translational Research, Institute for Personalized Cancer Therapy, M.D. Anderson Cancer Center
Ramon Kemp, Ph.D., Vice President, Head, Oncology EDL, Interim Head, Oncology MDL, GSK
Investor R&D Day Webcast Presentation and Registration Information
IDEAYA’s Investor R&D Day webcast presentation will be available on the company’s website, at its Investor Relations portal (View Source) in advance of the investor webcast presentation at approximately 6:00 am ET.
Registration is available at View Sourceevents or View Source